SCHEMBL20889293

SCHEMBL20889293

COc1cccc(CNc2c(-c3c(O)ccc4ccccc34)nc3ccccn23)c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SALL4 Q9UJQ4 12/20 0.80
TRIM24 O15164 1/20 0.58
TRIM33 Q9UPN9 1/20 0.58
KDM4E B2RXH2 1/20 0.49
NPC1 O15118 1/20 0.49
ALDH1A1 P00352 1/20 0.49
TP53 P04637 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NR1H4 Q96RI1 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
KMT2A Q03164 1/20 0.45
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBA3C P0DPH7 1/20 0.43
TUBA1B P68363 1/20 0.43
TUBA4A P68366 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20889748 0.89 SALL4 (1.00) SALL4TRIM24TRIM33KDM4EALDH1A1
SCHEMBL20889512 0.87 SALL4 (1.00) SALL4TRIM24TRIM33NR1H4L3MBTL1
SCHEMBL20889496 0.87 SALL4 (0.79) SALL4TRIM24TRIM33KDM4EALDH1A1
SCHEMBL20889289 0.84 SALL4 (0.60) SALL4KDM4ENPC1ALDH1A1TP53
SCHEMBL20889720 0.80 SALL4 (0.78) SALL4TRIM24TRIM33NPC1GAA
SCHEMBL20889695 0.79 SALL4 (0.81) SALL4TRIM24TRIM33KDM4E
SCHEMBL20889721 0.78 SALL4 (0.78) SALL4TRIM24TRIM33TUBB4ATUBB
SCHEMBL20889288 0.78 NR1H4 (0.57) SALL4KDM4ENPC1ALDH1A1TP53
SCHEMBL2989783 0.76 NR1H4 (0.63) SALL4KDM4ENPC1ALDH1A1TP53
SCHEMBL20889791 0.75 SALL4 (1.00) SALL4TRIM24TRIM33NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11530209-B2 Small molecule inhibition of transcription factor SALL4 and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-12-20 US disclosed
US-20200317664-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-10-08 US disclosed
WO-2019070943-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530209-B2 Small molecule inhibition of transcription factor SALL4 and uses thereof SALL4, GLI2, TCF4 SALL4 1/4885TRIM24 203/4885TRIM33 564/4885
US-20200317664-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF SALL4, GLI2, TCF4 SALL4 1/4885TRIM24 203/4885TRIM33 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.